Literature DB >> 1379929

Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat.

P Overton1, P J Elliott, R M Hagan, D Clark.   

Abstract

The effect of selective neurokinin (NK) receptor agonists on the activity of A9 and A10 dopamine cells was assessed using extracellular recording. A higher proportion of A10 cells which were administered the NK1 receptor agonist GR73632 or the NK3 receptor agonist senktide showed an effect, whereas the NK2 receptor agonist GR64349 did not discriminate as clearly between the two cell groups. The most frequently encountered response in all cases was an increase in firing rate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379929     DOI: 10.1016/0014-2999(92)90251-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  Substance P inhibits GABAB receptor signalling in the ventral tegmental area.

Authors:  Yan-Fang Xia; Elyssa B Margolis; Gregory O Hjelmstad
Journal:  J Physiol       Date:  2010-03-15       Impact factor: 5.182

3.  Blockade of tachykinin NK3 receptor reverses hypertension through a dopaminergic mechanism in the ventral tegmental area of spontaneously hypertensive rats.

Authors:  Helaine De Brito Gariepy; Réjean Couture
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

4.  NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens.

Authors:  Chinwe A Nwaneshiudu; Ellen M Unterwald
Journal:  J Neurochem       Date:  2010-09-28       Impact factor: 5.372

Review 5.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

6.  Cognitive performance in neurokinin 3 receptor knockout mice.

Authors:  R E Nordquist; M Delenclos; T M Ballard; H Savignac; M Pauly-Evers; L Ozmen; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-20       Impact factor: 4.530

7.  The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety.

Authors:  D M Walsh; S C Stratton; F J Harvey; I J Beresford; R M Hagan
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

8.  The neurokinin-3 (NK3) and the neurokinin-1 (NK1) receptors are differentially targeted to mesocortical and mesolimbic projection neurons and to neuronal nuclei in the rat ventral tegmental area.

Authors:  Andrée Lessard; Martin Savard; Fernand Gobeil; Joseph P Pierce; Virginia M Pickel
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

9.  Blockade of neurokinin-3 receptors modulates dopamine-mediated behavioral hyperactivity.

Authors:  Chinwe A Nwaneshiudu; Ellen M Unterwald
Journal:  Neuropharmacology       Date:  2009-06-03       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.